A Brief Introduction to Eribulin
Molecular Formula: C₄₀H₅₉NO₁₁
Molecular Weight:729.9
CAS No.:253128-41-5
Appearance:White to off-white crystalline powder
What is Eribulin?
- Eribulin is a chemotherapy drug.
- Eribulin API (Active Pharmaceutical Ingredient) is the active drug component used in the synthesis of Eribulin Mesylate.
- Eribulin Mesylate injection, an anti-cancer drug, was first launched by the Japanese pharmaceutical company Eisai, under the brand name Halaven.
- Eribulin Mesylate is suitable for certain patients with advanced cancer, especially those who have failed other chemotherapy regimens.
- Its effectiveness has been subjected to the most rigorous testing, and extensive clinical data have proven that eribulin has significant effects in the second-line treatment of advanced cancer, effectively extending patients’ survival time.
Highassay’s Eribulin
Highassay offers Eribulin API with a purity of 99%, and our manufacturing facility complies with GMP standards. The active ingredient and functions of Eribulin have been certified. With the expiration of the original drug’s patent, Eribulin, as a scarce resource, will experience its largest market growth. Whether for pharmaceutical production or research purposes, Highassay can provide you with the Eribulin you need.
For purchasing Eribulin, please choose Highassay. We look forward to your inquiry!
How does Eribulin work?
Eribulin inhibits microtubule dynamics and disrupts the formation of the spindle apparatus necessary for cancer cell division. As a result, cancer cells cannot complete division and eventually die. Patients may develop resistance to taxane-based drugs, but because Eribulin has a different mechanism of action than taxanes, it remains effective against cancer cells that have developed resistance to taxane-based drugs.
Eribulin-Based Drugs
- Eribulin Mesylate injection is indicated for patients with locally recurrent or metastatic breast cancer who have received at least two prior chemotherapy regimens (including anthracyclines and taxanes).
- Eribulin Mesylate injection is also indicated for patients with advanced soft tissue sarcoma (especially liposarcoma and leiomyosarcoma).
- Eribulin antibody-drug conjugates are a new type of Eribulin drug currently in clinical trials, offering greater targeting specificity and potentially fewer side effects. It is an innovative drug under development, with a completely different mechanism of action compared to Halaven. An example is MORAb-202.
Eribulin Administration
As a prescription medication, it is generally necessary to follow your doctor’s advice. Eribulin is administered in treatment cycles, typically 21 days per cycle. For some patients with liver dysfunction, the dosage needs to be adjusted according to the severity of the liver impairment. Regular health check-ups are also necessary during treatment with Eribulin to avoid exacerbating existing health problems.
Eribulin Side Effects
As a chemotherapy drug, Eribulin has quite a few side effects. These include nausea, fatigue, and hair loss. More serious symptoms can also occur, such as muscle weakness, irregular heartbeat, and even difficulty breathing. Hair loss is something that all patients undergoing chemotherapy experience, but the hair will grow back after the treatment ends; it is usually temporary, so there is no need to be overly anxious.
